Survival outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab: a comparison between ECOG performance status 0–1 and 2
Retrospective study compares survival outcomes between ECOG PS 0–1 and 2 in metastatic lung cancer, indicating significant prognostic factors.
Key Points
This study aimed to explore the influence of ECOG performance status on survival outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Retrospective, single-center study including 272 patients with metastatic non-small-cell lung cancer who received nivolumab.
ECOG PS and disease characteristics were recorded prior to starting nivolumab.
Survival analysis focused on overall survival and progression-free survival.
Median PFS was 3.6 months and median OS was 9.1 months for the cohort.
ECOG PS 2 associated with shorter PFS (HR = 1.48; 95% CI 1.06–2.07; p = 0.022) and OS (HR = 1.89; 95% CI 1.32–2.72; p < 0.001).
Negative PD-L1 status (< 1%) linked to reduced PFS (HR = 1.51; 95% CI 1.09–2.09; p = 0.012) and OS (HR = 1.59; 95% CI 1.11–2.27; p = 0.011).